Therapeutic combinations comprising anti-FOLR1 immunoconjugates
AU2026205501A1Pending Publication Date: 2026-07-30IMMUNOGEN INC
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- IMMUNOGEN INC
- Filing Date
- 2026-07-10
- Publication Date
- 2026-07-30
Smart Images
Figure 00000096_0000 
Figure 00000097_0000 
Figure 00000097_0001
Abstract
Abstract Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti- VEGF agents (e.g., bevacizumab), a platinum-based agent, and / or doxorubicin are provided. Methods of administering the combinations to treat cancers, e.g., ovarian cancers, with greater clinical efficacy and / or decreased toxicity are also provided. Abstract 20 26 20 55 01 10 J ul 2 02 6 2 0 2 6 2 0 5 5 0 1 1 0 J u l 2 0 2 6
Need to check novelty before this filing date? Find Prior Art